SCHEMBL19668708

SCHEMBL19668708

Cc1ccnc(OCC(N)c2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ SCN4A P35499 10/20 0.53
▸ TACR1 P25103 5/20 0.50
▸ CRHR1 P34998 5/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19668457 0.79 SCN4A (0.59) SCN4ATACR1
SCHEMBL19668462 0.78 TACR1 (0.53) SCN4ATACR1
SCHEMBL15086909 0.75 UHRF1 (0.43) CRHR1
SCHEMBL19685914 0.75 SCN4A (0.69) SCN4ATACR1
SCHEMBL19668710 0.75 NOS2 (0.43) CRHR1
SCHEMBL19685935 0.74 SCN4A (0.68) SCN4ATACR1
SCHEMBL12266585 0.74 SCN4A (0.58) SCN4ATACR1
SCHEMBL21325170 0.74 SCN4A (0.74) SCN4ATACR1
SCHEMBL15034203 0.74 RXRA (0.42) CRHR1
Hydrochloric Acid SCHEMBL19668696 0.73 SCN4A (0.66) SCN4ATACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11492325-B2 Compounds as inhibitors of sodium channels HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2022-11-08 — — US disclosed
US-20190270696-A1 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2019-09-05 — — US disclosed
US-20190270696-A1 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2019-09-05 — — US disclosed
EP-3494105-A2 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS Human Biomolecular Research Institute (US) 2019-06-12 — — EP disclosed
WO-2017210371-A2 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2017-12-07 — — WO disclosed
WO-2017210371-A2 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2017-12-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190270696-A1 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS SCN1B, CACNA1E, SCN2B SCN4A 48/4885TACR1 174/4885CRHR1 1215/4885
US-11492325-B2 Compounds as inhibitors of sodium channels SCN1B, CACNA1E, SCN2B SCN4A 48/4885TACR1 174/4885CRHR1 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback